Connect Biopharma is trading at $0.87, up 9.51%, with biotech-sector strength the likeliest available explanation.
- Supplied sector context reports XBI up 3.64% pre-market; no source directly confirms this caused the stock’s gain.
- No new company-specific announcement was identified for October 22; the company’s latest listed press release is dated September 30.
- Broader market futures are lower, so general market direction does not explain the rise.